(HealthDay News) — The Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx) has been revised to simplify diagnoses into 4 classes, according to a consensus statement published in JAMA Network Open.
Researchers revised the MPATH-Dx version 1.0 classification tool using feedback from dermatopathologists and members of the International Melanoma Pathology Study Group. All feedback was integrated into an updated and refined MPATH-Dx version 2.0.
The researchers noted that in order to improve diagnostic concordance and provide more explicit guidance for treatment, the new MPATH-Dx version 2.0 schema simplifies the original 5-class hierarchy into 4 classes.
Histopathological criteria for classification of class I and II lesions are clearly defined in the new version. Specific provisions are made for the most frequently encountered low-cumulative sun damage pathway of melanoma progression and other less common pathways to melanoma.
Guidance is provided for classifying intermediate class II tumors vs melanoma, and a subset of pT1a melanomas with very low risk is recognized.
“We expect that the implementation of the new revised MPATH-Dx V2.0 schema into routine practice will provide a robust tool and adjunct for standardized diagnostic reporting of melanocytic lesions and management of patients to the benefit of both health care practitioners and patients,” the study authors wrote.
Several authors disclosed financial ties to the biotechnology and pharmaceutical industries.